[
  {
    "ts": null,
    "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q1 2025 Update",
    "summary": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q1 2025 Update",
    "url": "https://finnhub.io/api/news?id=e27504393d6270f71f4779aed94b422dee3a3fcabc889d6582ddb2468c20c3d3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747865679,
      "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q1 2025 Update",
      "id": 134631523,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e27504393d6270f71f4779aed94b422dee3a3fcabc889d6582ddb2468c20c3d3"
    }
  },
  {
    "ts": null,
    "headline": "The FDA Takes a Trial-Lawyer Turn",
    "summary": "The FDA Takes a Trial-Lawyer Turn",
    "url": "https://finnhub.io/api/news?id=982aa4f4432189580bd5c9f9aa05593ee03b460e980f5d00c7dc0e81dc79fea4",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747849260,
      "headline": "The FDA Takes a Trial-Lawyer Turn",
      "id": 134633115,
      "image": "",
      "related": "JNJ",
      "source": "DowJones",
      "summary": "The FDA Takes a Trial-Lawyer Turn",
      "url": "https://finnhub.io/api/news?id=982aa4f4432189580bd5c9f9aa05593ee03b460e980f5d00c7dc0e81dc79fea4"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (NYSE:JNJ) FDA Panel Supports DARZALEX FASPRO®? for High-Risk Multiple Myeloma",
    "summary": "Johnson & Johnson (NYSE:JNJ) recently garnered attention when the FDA's Oncologic Drugs Advisory Committee voted favorably on the use of DARZALEX FASPRO® for high-risk smoldering multiple myeloma. This announcement comes amid a broad market environment where the S&P 500 has faced slight declines. The company’s shares increased 3.52% over the last week, possibly bolstered by these positive regulatory outcomes. As broader market factors weighed on indices, with the S&P 500 also navigating...",
    "url": "https://finnhub.io/api/news?id=acb25ab16e4c49f1fbfd8a771cddc95a5a1ce3b99570292c0500e9f9ee0b6fd1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747848792,
      "headline": "Johnson & Johnson (NYSE:JNJ) FDA Panel Supports DARZALEX FASPRO®? for High-Risk Multiple Myeloma",
      "id": 134628228,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) recently garnered attention when the FDA's Oncologic Drugs Advisory Committee voted favorably on the use of DARZALEX FASPRO® for high-risk smoldering multiple myeloma. This announcement comes amid a broad market environment where the S&P 500 has faced slight declines. The company’s shares increased 3.52% over the last week, possibly bolstered by these positive regulatory outcomes. As broader market factors weighed on indices, with the S&P 500 also navigating...",
      "url": "https://finnhub.io/api/news?id=acb25ab16e4c49f1fbfd8a771cddc95a5a1ce3b99570292c0500e9f9ee0b6fd1"
    }
  },
  {
    "ts": null,
    "headline": "Wasatch Global Value Fund Q1 2025 Commentary",
    "summary": "Wasatch Global Value FundâInvestor Class returned 11.65% in the first quarter of 2024, outperforming the MSCI AC World Value Index. Read more here.",
    "url": "https://finnhub.io/api/news?id=358ba00e56c1f00d27aca22b08d4c6dc9d2d2a95e97a1b095be329ad41f9458b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747846020,
      "headline": "Wasatch Global Value Fund Q1 2025 Commentary",
      "id": 134630187,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2193247114/image_2193247114.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Wasatch Global Value FundâInvestor Class returned 11.65% in the first quarter of 2024, outperforming the MSCI AC World Value Index. Read more here.",
      "url": "https://finnhub.io/api/news?id=358ba00e56c1f00d27aca22b08d4c6dc9d2d2a95e97a1b095be329ad41f9458b"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference",
    "summary": "Johnson & Johnson will present at the Bernstein’s 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 9:00 a.m. Eastern...",
    "url": "https://finnhub.io/api/news?id=159a92bae0e1ec36d2a2283baba825611813a8f84bd56e577c92054293495625",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747845663,
      "headline": "Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference",
      "id": 134629661,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson will present at the Bernstein’s 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 9:00 a.m. Eastern...",
      "url": "https://finnhub.io/api/news?id=159a92bae0e1ec36d2a2283baba825611813a8f84bd56e577c92054293495625"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know",
    "summary": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=75dcaa1518c3608c8e7b029fe8b210af4b7fa82103557ec1998145c73344011f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747832415,
      "headline": "Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know",
      "id": 134628229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=75dcaa1518c3608c8e7b029fe8b210af4b7fa82103557ec1998145c73344011f"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson's (NYSE:JNJ) Shareholders Will Receive A Bigger Dividend Than Last Year",
    "summary": "Johnson & Johnson ( NYSE:JNJ ) will increase its dividend from last year's comparable payment on the 10th of June to...",
    "url": "https://finnhub.io/api/news?id=d85a582819e43740037ffd1d6726bc252750a14ccccd5d84f2dcac8763e3a803",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747831771,
      "headline": "Johnson & Johnson's (NYSE:JNJ) Shareholders Will Receive A Bigger Dividend Than Last Year",
      "id": 134628230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson ( NYSE:JNJ ) will increase its dividend from last year's comparable payment on the 10th of June to...",
      "url": "https://finnhub.io/api/news?id=d85a582819e43740037ffd1d6726bc252750a14ccccd5d84f2dcac8763e3a803"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Looks Like A Great Play At Current Valuations",
    "summary": "Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers.",
    "url": "https://finnhub.io/api/news?id=a926781e85b4794d8dfc4b02946c645e3c548a2b3de04af57250c83422ef2b47",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747830005,
      "headline": "Pfizer Looks Like A Great Play At Current Valuations",
      "id": 134626678,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359138081/image_1359138081.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers.",
      "url": "https://finnhub.io/api/news?id=a926781e85b4794d8dfc4b02946c645e3c548a2b3de04af57250c83422ef2b47"
    }
  },
  {
    "ts": null,
    "headline": "J&J: launches new ICE catheter in the United States",
    "summary": "Johnson & Johnson MedTech announces that the Soundstar Crystal ultrasound catheter is now available in the United States for ICE imaging in cardiac ablation procedures. ICE provides real-time...",
    "url": "https://finnhub.io/api/news?id=cf99837ccd98a5bcb12d1ab5a80a468845ce885602f43fb7ce9307b768a53e8e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747818803,
      "headline": "J&J: launches new ICE catheter in the United States",
      "id": 134625198,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson MedTech announces that the Soundstar Crystal ultrasound catheter is now available in the United States for ICE imaging in cardiac ablation procedures. ICE provides real-time...",
      "url": "https://finnhub.io/api/news?id=cf99837ccd98a5bcb12d1ab5a80a468845ce885602f43fb7ce9307b768a53e8e"
    }
  },
  {
    "ts": null,
    "headline": "Forget About Dividend Yield, Do This Instead",
    "summary": "Dividend growth and low payout ratios are key for long-term compounding. Click here for more information on Dividend Investing Strategies.",
    "url": "https://finnhub.io/api/news?id=5b931bd91eaf816029ef734fe292646a879ad80a5bc402c1a2ed4634ab54440a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747818000,
      "headline": "Forget About Dividend Yield, Do This Instead",
      "id": 134625239,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/175534967/image_175534967.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Dividend growth and low payout ratios are key for long-term compounding. Click here for more information on Dividend Investing Strategies.",
      "url": "https://finnhub.io/api/news?id=5b931bd91eaf816029ef734fe292646a879ad80a5bc402c1a2ed4634ab54440a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson MedTech Launches SOUNDSTAR CRYSTAL in the US, Redefining Image Clarity in 2D Intracardiac Imaging",
    "summary": "Johnson & Johnson: * JOHNSON & JOHNSON MEDTECH LAUNCHES SOUNDSTAR CRYSTAL™ INTHE US,REDEFINING IMAGE CLARITY IN 2D INTRACARDIAC IMAGINGSource text:Further company coverage: ...",
    "url": "https://finnhub.io/api/news?id=a6f0d2dcfb4a0a412206f33537ca262003f1c748456c16210cc972f0cf54fc5f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747817898,
      "headline": "Johnson & Johnson MedTech Launches SOUNDSTAR CRYSTAL in the US, Redefining Image Clarity in 2D Intracardiac Imaging",
      "id": 134625052,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson: * JOHNSON & JOHNSON MEDTECH LAUNCHES SOUNDSTAR CRYSTAL™ INTHE US,REDEFINING IMAGE CLARITY IN 2D INTRACARDIAC IMAGINGSource text:Further company coverage: ...",
      "url": "https://finnhub.io/api/news?id=a6f0d2dcfb4a0a412206f33537ca262003f1c748456c16210cc972f0cf54fc5f"
    }
  },
  {
    "ts": null,
    "headline": "My Dividend Stock Portfolio: New All-Time Dividend Record In April - 100 Holdings With 14 Buys",
    "summary": "My Dividend Stock Portfolio: New All-Time Dividend Record In April - 100 Holdings With 14 Buys",
    "url": "https://finnhub.io/api/news?id=da857ba038502fb2801876c07073c96e54676960374534733580830e88991dab",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747815000,
      "headline": "My Dividend Stock Portfolio: New All-Time Dividend Record In April - 100 Holdings With 14 Buys",
      "id": 134624799,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=da857ba038502fb2801876c07073c96e54676960374534733580830e88991dab"
    }
  },
  {
    "ts": null,
    "headline": "2 Companies Now Have Credit Ratings Higher Than The U.S.",
    "summary": "2 Companies Now Have Credit Ratings Higher Than The U.S.",
    "url": "https://finnhub.io/api/news?id=cbaac57c55880d1f36d4b82f821c9af37c936f79f47216b34f4e13f9b5fac963",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747814421,
      "headline": "2 Companies Now Have Credit Ratings Higher Than The U.S.",
      "id": 134632225,
      "image": "",
      "related": "JNJ",
      "source": "DowJones",
      "summary": "2 Companies Now Have Credit Ratings Higher Than The U.S.",
      "url": "https://finnhub.io/api/news?id=cbaac57c55880d1f36d4b82f821c9af37c936f79f47216b34f4e13f9b5fac963"
    }
  },
  {
    "ts": null,
    "headline": "How My Parents Retired At 60, Fueled By Dividend Income",
    "summary": "How My Parents Retired At 60, Fueled By Dividend Income",
    "url": "https://finnhub.io/api/news?id=df7bc90c827d21fa1f3e1c7e6495d74dd4bcd9d37a0ffa27c3ba5dad026bc240",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747812600,
      "headline": "How My Parents Retired At 60, Fueled By Dividend Income",
      "id": 134624438,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=df7bc90c827d21fa1f3e1c7e6495d74dd4bcd9d37a0ffa27c3ba5dad026bc240"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (NYSE:JNJ) Hit with $147M Verdict in Landmark Antitrust Case Over Reprocessed Medical Devices",
    "summary": "A federal jury in Santa Ana has ordered Johnson & Johnson (NYSE:JNJ) to pay $147 million after its Biosense Webster unit was found guilty of violating antitrust laws. The court ruled J&J illegally withheld clinical support from hospitals using FDA-approved reprocessed catheters, directly undermining competition in the single-use device (SUD) market. Plaintiff Innovative Health secured […]",
    "url": "https://finnhub.io/api/news?id=88834d23c82aa9a92e374a153f54b586b2fbbb8cd0ef9d92304ae37bc4281d6e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747797703,
      "headline": "Johnson & Johnson (NYSE:JNJ) Hit with $147M Verdict in Landmark Antitrust Case Over Reprocessed Medical Devices",
      "id": 134628231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "A federal jury in Santa Ana has ordered Johnson & Johnson (NYSE:JNJ) to pay $147 million after its Biosense Webster unit was found guilty of violating antitrust laws. The court ruled J&J illegally withheld clinical support from hospitals using FDA-approved reprocessed catheters, directly undermining competition in the single-use device (SUD) market. Plaintiff Innovative Health secured […]",
      "url": "https://finnhub.io/api/news?id=88834d23c82aa9a92e374a153f54b586b2fbbb8cd0ef9d92304ae37bc4281d6e"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Announces U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Approves the Approval of the Benefit-Risk Profile of Single- Agent Darzalex Faspro®?",
    "summary": "Johnson & Johnson announced the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee voted in favor of the benefit-risk profile of single-agent DARZALEX FASPRO®? for the treatment...",
    "url": "https://finnhub.io/api/news?id=d9fb3e53f1d4a02987af09b87d6fd011074e0b574e0124af5f2dc32c1fa8a67b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747794045,
      "headline": "Johnson & Johnson Announces U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Approves the Approval of the Benefit-Risk Profile of Single- Agent Darzalex Faspro®?",
      "id": 134622173,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announced the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee voted in favor of the benefit-risk profile of single-agent DARZALEX FASPRO®? for the treatment...",
      "url": "https://finnhub.io/api/news?id=d9fb3e53f1d4a02987af09b87d6fd011074e0b574e0124af5f2dc32c1fa8a67b"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Kings - May 2025",
    "summary": "Dividend Kings have outperformed the S&P 500 year-to-date, but recent momentum has slowed. Discover the full story here.",
    "url": "https://finnhub.io/api/news?id=783cf3a9b25bba76f793a8bcb80d813359f7ffa3eae279f58b34b03c0b343593",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747792261,
      "headline": "Best Dividend Kings - May 2025",
      "id": 134622076,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2166444456/image_2166444456.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Dividend Kings have outperformed the S&P 500 year-to-date, but recent momentum has slowed. Discover the full story here.",
      "url": "https://finnhub.io/api/news?id=783cf3a9b25bba76f793a8bcb80d813359f7ffa3eae279f58b34b03c0b343593"
    }
  }
]